TCTC Holdings LLC Has $1.64 Million Stock Position in Danaher Co. (NYSE:DHR)

TCTC Holdings LLC reduced its position in Danaher Co. (NYSE:DHR) by 2.1% in the 4th quarter, Holdings Channel reports. The firm owned 7,157 shares of the conglomerate’s stock after selling 153 shares during the quarter. TCTC Holdings LLC’s holdings in Danaher were worth $1,643,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently bought and sold shares of DHR. Heck Capital Advisors LLC bought a new position in Danaher in the fourth quarter worth $27,000. Decker Retirement Planning Inc. bought a new position in Danaher in the fourth quarter worth $31,000. Golden State Wealth Management LLC bought a new position in shares of Danaher during the fourth quarter valued at $31,000. Strategic Financial Concepts LLC bought a new position in shares of Danaher during the fourth quarter valued at $31,000. Finally, Pineridge Advisors LLC lifted its holdings in shares of Danaher by 63.3% during the fourth quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate’s stock valued at $34,000 after acquiring an additional 57 shares during the period. 79.05% of the stock is owned by institutional investors.

Insider Transactions at Danaher

In other news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 11.10% of the company’s stock.

Danaher Price Performance

Danaher stock opened at $211.09 on Monday. The firm has a market capitalization of $150.87 billion, a P/E ratio of 39.98, a PEG ratio of 2.66 and a beta of 0.82. Danaher Co. has a 1 year low of $196.80 and a 1 year high of $281.70. The business has a 50-day moving average of $220.07 and a 200-day moving average of $240.45. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last posted its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting the consensus estimate of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter last year, the company posted $2.09 earnings per share. On average, equities analysts anticipate that Danaher Co. will post 7.63 EPS for the current year.

Danaher Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be given a dividend of $0.32 per share. This is a positive change from Danaher’s previous quarterly dividend of $0.27. This represents a $1.28 annualized dividend and a dividend yield of 0.61%. The ex-dividend date is Friday, March 28th. Danaher’s payout ratio is presently 24.24%.

Wall Street Analysts Forecast Growth

DHR has been the subject of a number of analyst reports. Scotiabank initiated coverage on Danaher in a report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price objective for the company. Wells Fargo & Company cut their price objective on Danaher from $280.00 to $240.00 and set an “equal weight” rating for the company in a report on Thursday, January 30th. Stifel Nicolaus raised Danaher from a “hold” rating to a “buy” rating and set a $260.00 price objective for the company in a report on Friday. Raymond James reissued a “market perform” rating on shares of Danaher in a report on Monday, February 3rd. Finally, Jefferies Financial Group cut their price objective on Danaher from $285.00 to $260.00 and set a “buy” rating for the company in a report on Wednesday, January 29th. Six research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $277.76.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.